TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces that discussions with the potential Latin American partner with which it executed an LOI in 2012 have been discontinued due to a recent change in the potential partner’s management and corporate strategy. Antibe’s CEO Dan Legault stated, “Although we were looking forward to working with this partner, we are gratified that our work on ATB-346 was validated by their due diligence studies. We are moving quickly into our next phase of development while continuing discussions with our other potential partners”. With the completion of its planned pre-clinical program, Antibe is on schedule to initiate its first-in-human trials in June, pending regulatory approval, and is continuing its regional partnering strategy including ongoing discussions with potential clinical partners.
Help employers find you! Check out all the jobs and post your resume.
